- Home
- BWBBP vs CGEN Comparison
BWBBP vs CGEN Comparison
Compare BWBBP & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BWBBP
- CGEN
- Stock Information
- Founded
- BWBBP N/A
- CGEN 1993
- Country
- BWBBP United States
- CGEN Israel
- Employees
- BWBBP 258
- CGEN N/A
- Industry
- BWBBP Major Banks
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BWBBP Finance
- CGEN Health Care
- Exchange
- BWBBP Nasdaq
- CGEN Nasdaq
- Market Cap
- BWBBP N/A
- CGEN 134.3M
- IPO Year
- BWBBP N/A
- CGEN 2000
- Fundamental
- Price
- BWBBP $20.04
- CGEN $1.65
- Analyst Decision
- BWBBP
- CGEN Strong Buy
- Analyst Count
- BWBBP 0
- CGEN 1
- Target Price
- BWBBP N/A
- CGEN $4.00
- AVG Volume (30 Days)
- BWBBP N/A
- CGEN 470.1K
- Earning Date
- BWBBP N/A
- CGEN 11-12-2024
- Dividend Yield
- BWBBP N/A
- CGEN N/A
- EPS Growth
- BWBBP N/A
- CGEN N/A
- EPS
- BWBBP N/A
- CGEN 0.02
- Revenue
- BWBBP N/A
- CGEN $59,852,000.00
- Revenue This Year
- BWBBP N/A
- CGEN $57.27
- Revenue Next Year
- BWBBP N/A
- CGEN N/A
- P/E Ratio
- BWBBP N/A
- CGEN $85.40
- Revenue Growth
- BWBBP N/A
- CGEN 698.03
- 52 Week Low
- BWBBP N/A
- CGEN $1.35
- 52 Week High
- BWBBP N/A
- CGEN $3.03
- Technical
- Relative Strength Index (RSI)
- BWBBP 60.55
- CGEN 56.57
- Support Level
- BWBBP $18.56
- CGEN $1.47
- Resistance Level
- BWBBP $19.00
- CGEN $1.65
- Average True Range (ATR)
- BWBBP 0.60
- CGEN 0.10
- MACD
- BWBBP 0.17
- CGEN 0.00
- Stochastic Oscillator
- BWBBP 68.33
- CGEN 80.80
About BWBBP Bridgewater Bancshares Inc. Depositary Shares Each Representing a 1/100th Interest in a Share of 5.875% Non-Cumulative Perpetual Preferred Stock Series A
Bridgewater Bancshares Inc offers retail and commercial loan and deposit services to customers within the Minneapolis-St. Paul-Bloomington, MN-WI Metropolitan Statistical Area. The company engages in providing a wide range of deposit and lending products. Its products and services include commercial deposits, loans, online business services, credit card, mobile banking, and remote deposit services.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.